Please Wait.....
Report
Global Obesity Treatment Market
Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research
Global obesity treatment market is expected to reach USD 115.25 million by 2032 from USD 38.46 million in 2024, growing at a CAGR of 14.7% in the forecast period of 2025 to 2032.
Market Segmentation:
Global Obesity Treatment Market, Treatment Type (Pharmacological Treatments (Anti-obesity Drugs), Bariatric Surgery, Behavioral & Lifestyle Therapy, Non-Invasive/ Endoscopic Procedures, and Medical Devices & Technologies), Age Group (Adult Obesity Treatment, Geriatric Obesity Treatment, and Pediatric Obesity Treatment), Distribution Channel (Online Pharmacies, Retail Pharmacies, Weight Management Clinics, Hospital Pharmacies, and Wellness & Fitness Centers), Patient Type (Class III, Class II, and Class I), Country (U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Netherlands, Switzerland, Norway, Austria, Ireland, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Chile, Peru, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Kuwait, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2032
Overview of Global Obesity Treatment Market Dynamics:
Driver
- Integration of Digital Health Solutions in Obesity Treatment
Restraint
- Anti-Obesity Drugs and Surgical Interventions Carry Risks
Opportunity
- Increasing Prevalence of Lifestyle Related Diseases
Market Players:
The key market players operating in the global obesity treatment market are listed below:
- Novo Nordisk A/S
- Eli Lilly and Company
- Medtronic Plc.
- Boston Scientific Corporation
- Johnson & Johnson Services, Inc.
- Astrazeneca
- Sanofi
- Allurion Technologie
- Amger
- Raziel
- Reshape Lifesciences
- Spatz FGIA
- Viking Therapeutics
- COUSIN SURGERY
- Currax Pharmaceuticals LLC
- Arena Pharmaceuticals Ltd
- VIVUS LLC.
- ZEALAND PHARMA
- Noom, Inc.
- Omada Health Inc
- Saniona
- USGI Medical
- F. HOFFMANN LA-ROCHE AG
- GSK plc
- Morphic Medical, Inc.
- Fitterfly
- Altimmune.
TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF THE GLOBAL OBESITY TREATMENT MARKET 44
1.4 CURRENCY AND PRICING 45
1.5 LIMITATIONS 45
1.6 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 DBMR TRIPOD DATA VALIDATION MODEL 52
2.5 MULTIVARIATE MODELLING 55
2.6 TREATMENT TYPE LIFELINE CURVE 55
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.8 DBMR MARKET POSITION GRID 57
2.9 MARKET END USER COVERAGE GRID 58
2.10 VENDOR SHARE ANALYSIS 59
2.11 SECONDARY SOURCES 60
2.12 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 66
4.1 PORTER'S FIVE FORCES 69
4.2 PESTEL ANALYSIS 70
4.3 EPIDEMIOLOGY: GLOBAL OBESITY TREATMENT MARKET 71
4.4 DRUG TREATMENT RATE BY MATURED MARKETS: GLOBAL OBESITY TREATMENT MARKET 78
4.5 DRUG 85
4.6 WORD PIPELINE 88
5 REGULATORY FRAMEWORK FOR THE GLOBAL OBESITY TREATMENT MARKET 120
5.1 REGULATORY APPROVAL PATHWAYS 122
5.2 LICENSING AND REGISTRATION 122
5.3 REGULATORY APPROVAL PATHWAYS 123
5.4 LICENSING AND REGISTRATION 123
5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 124
6 MARKET OVERVIEW 125
6.1 DRIVERS 127
6.1.1 INCREASING PREVALENCE OF OBESITY 127
6.1.2 INNOVATIONS IN ANTI-OBESITY MEDICATIONS 129
6.1.3 GROWTH IN BARIATRIC AND METABOLIC SURGERIES. 130
6.1.4 INTEGRATION OF DIGITAL HEALTH SOLUTIONS IN OBESITY TREATMENT 130
6.2 RESTRAINTS 132
6.2.1 ANTI-OBESITY DRUGS AND SURGICAL INTERVENTIONS CARRY RISKS 132
6.2.2 HIGH RELAPSE RATES POST-TREATMENT OF OBESITY 132
6.3 OPPORTUNITIES 133
6.3.1 INCREASING PREVALENCE OF LIFESTYLE RELATED DISEASES 133
6.3.2 RISING DISPOSABLE INCOME ENHANCING THE PURCHASING POWER FOR OBESITY TREATMENT RELATED PRODUCTS 134
6.3.3 RISE IN STRATEGIC INITIATIVES AND LAUNCHES BY MARKET PLAYERS 134
6.4 CHALLENGES 135
6.4.1 LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT 135
6.4.2 ADDRESSAL OF THE LIFESTYLE AND BEHAVIORAL CHANGES 135
7 GLOBAL OBESITY TREATMENT MARKET, BY TREATMENT TYPE 137
7.1 OVERVIEW 138
7.2 PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) 141
7.2.1 GLP-1 RECEPTOR AGONISTS 141
7.2.2 DUAL GIP/ GLP-1 RECEPTOR AGONISTS 141
7.2.2.1 PHENTERMINE 142
7.2.2.2 PHENTERMINE-TOPIRAMATE 142
7.2.2.3 NALTREXONE-BUPROPION 142
7.2.3 LIPASE INHIBITORS 142
7.2.4 DEOXYCHOLIC ACID 142
7.2.5 OTHERS 142
7.3 BARIATRIC SURGERY 142
7.3.1 RESTRICTIVE SURGERIES 143
7.3.1.1 SLEEVE GASTRECTOMY 143
7.3.1.2 ADJUSTABLE GASTRIC BANDING 143
7.3.2 COMBINATION SURGERIES 144
7.3.2.1 ROUX-EN-Y GASTRIC BYPASS (RYGB) 144
7.3.2.2 MINI-GASTRIC BYPASS (MGB) 144
7.3.3 MALABSORPTIVE SURGERIES 144
7.3.3.1 LAPAROSCOPIC SURGERY 144
7.3.3.2 ROBOTIC-ASSISTED SURGERY 144
7.3.3.3 OPEN SURGERY 144
7.4 BEHAVIORAL & LIFESTYLE THERAPY 145
7.4.1 DIETARY INTERVENTIONS 145
7.4.2 BEHAVIORAL MODIFICATION THERAPY 145
7.4.3 PHYSICAL ACTIVITY PROGRAMS 145
7.4.4 PSYCHOLOGICAL COUNSELING 145
7.5 NON-INVASIVE/ ENDOSCOPIC PROCEDURES 146
7.5.1 ENDOSCOPIC SLEEVE GASTROPLASTY (ESG) 146
7.5.2 INTRAGASTRIC BALLOON (IGB) 147
7.5.2.1 ORBERA INTRAGASTRIC BALLOON 147
7.5.2.2 SPATZ ADJUSTABLE BALLOON SYSTEM 147
7.5.3 ASPIRATION THERAPY (ASPIREASSIST) 147
7.5.4 TRANSORAL GASTROPLASTY (TOGA) 147
7.6 MEDICAL DEVICES & TECHNOLOGIES 148
7.6.1 ARTIFICIAL INTELLIGENCE & DIGITAL WEIGHT MANAGEMENT PLATFORMS 148
7.6.2 GASTRIC ELECTRICAL STIMULATION DEVICES (MAESTRO SYSTEM) 148
8 GLOBAL OBESITY TREATMENT MARKET, BY AGE GROUP 149
8.1 OVERVIEW 150
8.2 ADULT OBESITY TREATMENT 153
8.3 GERIATRIC OBESITY TREATMENT 153
8.4 PEDIATRIC OBESITY TREATMENT 154
9 GLOBAL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL 155
9.1 OVERVIEW 156
9.2 ONLINE PHARMACIES 159
9.3 RETAIL PHARMACIES 159
9.4 WEIGHT MANAGEMENT CLINICS 160
9.5 HOSPITAL PHARMACIES 160
9.6 WELLNESS & FITNESS CENTERS 161
10 GLOBAL OBESITY TREATMENT MARKET, BY PATIENT TYPE 162
10.1 OVERVIEW 163
10.2 CLASS III 166
10.3 CLASS II 166
10.4 CLASS I 167
11 GLOBAL OBESITY TREATMENT MARKET, BY REGION 168
11.1 OVERVIEW 169
11.2 NORTH AMERICA 172
11.2.1 U.S. 177
11.2.2 MEXICO 182
11.2.3 CANADA 187
11.3 EUROPE 192
11.3.1 UNITED KINGDOM 198
11.3.2 GERMANY 203
11.3.3 FRANCE 208
11.3.4 ITALY 213
11.3.5 SPAIN 218
11.3.6 RUSSIA 223
11.3.7 TURKEY 228
11.3.8 NETHERLANDS 233
11.3.9 SWITZERLAND 238
11.3.10 POLAND 243
11.3.11 IRELAND 248
11.3.12 AUSTRIA 253
11.3.13 NORWAY 258
11.3.14 REST OF EUROPE 263
11.4 ASIA-PACIFIC 264
11.4.1 CHINA 270
11.4.2 JAPAN 275
11.4.3 INDIA 280
11.4.4 AUSTRALIA 285
11.4.5 SOUTH KOREA 290
11.4.6 TAIWAN 295
11.4.7 SINGAPORE 300
11.4.8 MALAYSIA 305
11.4.9 THAILAND 310
11.4.10 INDONESIA 315
11.4.11 PHILIPPINES 320
11.4.12 VIETNAM 325
11.4.13 REST OF ASIA-PACIFIC 330
11.5 MIDDLE EAST AND AFRICA 331
11.5.1 SAUDI ARABIA 337
11.5.2 EGYPT 342
11.5.3 KUWAIT 347
11.5.4 SOUTH AFRICA 352
11.5.5 UNITED ARAB EMIRATES 357
11.5.6 ISRAEL 362
11.5.7 REST OF MIDDLE EAST AND AFRICA 367
11.6 SOUTH AMERICA 368
11.6.1 BRAZIL 374
11.6.2 ARGENTINA 379
11.6.3 CHILE 384
11.6.4 PERU 389
11.6.5 REST OF SOUTH AMERICA 394
12 GLOBAL OBESITY TREATMENT MARKET, COMPANY LANDSCAPE 395
12.1 COMPANY SHARE ANALYSIS: GLOBAL 395
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 396
12.3 COMPANY SHARE ANALYSIS: EUROPE 397
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 398
13 SWOT ANALYSIS 399
14 COMPANY PROFILE 400
14.1 NOVO NORDISK A/S 400
14.1.1 COMPANY SNAPSHOT 400
14.1.2 REVENUE ANALYSIS 400
14.1.3 COMPANY SHARE ANALYSIS 401
14.1.4 PRODUCT PORTFOLIO 401
14.1.5 RECENT DEVELOPMENT 402
14.2 ELI LILLY AND COMPANY 403
14.2.1 COMPANY SNAPSHOT 403
14.2.2 REVENUE ANALYSIS 403
14.2.3 COMPANY SHARE ANALYSIS 404
14.2.4 PRODUCT PORTFOLIO 404
14.2.5 RECENT DEVELOPMENT/NEWS 405
14.3 MEDTRONIC 406
14.3.1 COMPANY SNAPSHOT 406
14.3.2 REVENUE ANALYSIS 406
14.3.3 COMPANY SHARE ANALYSIS 407
14.3.4 PRODUCT PORTFOLIO 407
14.3.5 RECENT DEVELOPMENT 408
14.4 BOSTON SCIENTIFIC CORPORATION 409
14.4.1 COMPANY SNAPSHOTS 409
14.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 410
14.4.3 COMPANY SHARE ANALYSIS 410
14.4.4 PRODUCT PORTFOLIO 410
14.4.5 RECENT DEVELOPMENT 411
14.5 JOHNSON & JOHNSON SERVICES, INC. 412
14.5.1 COMPANY SNAPSHOT 412
14.5.2 REVENUE ANALYSIS 412
14.5.3 COMPANY SHARE ANALYSIS 413
14.5.4 PRODUCT PORTFOLIO 413
14.5.5 RECENT DEVELOPMENT/NEWS 414
14.6 ALTIMMUNE 415
14.6.1 COMPANY SNAPSHOT 415
14.6.2 PIPELINE PORTFOLIO 415
14.6.3 RECENT UPDATES 416
14.7 ASTRAZENECA 417
14.7.1 COMPANY SNAPSHOT 417
14.7.2 REVENUE ANALYSIS 417
14.7.3 PRODUCT PORTFOLIO 418
14.7.4 RECENT DEVELOPMENT/NEWS 418
14.8 ALLURION 420
14.8.1 COMPANY SNAPSHOT 420
14.8.2 REVENUE ANALYSIS 420
14.8.3 PRODUCT PORTFOLIO 421
1.1.5 RECENT DEVELOPMENT/NEWS 421
14.9 AMGEN 425
14.9.1 COMPANY SNAPSHOT 425
14.9.2 REVENUE ANALYSIS 425
14.9.3 PRODUCT PORTFOLIO 426
1.1.13 RECENT DEVELOPMENT/NEWS 426
14.10 ARENA PHARMACEUTICALS LTD 428
14.10.1 COMPANY SNAPSHOT 428
14.10.2 PRODUCT PORTFOLIO 428
14.10.3 RECENT DEVELOPMENT 428
14.11 CURRAX PHARMACEUTICALS LLC 429
14.11.1 COMPANY SNAPSHOT 429
14.11.2 PRODUCT PORTFOLIO 429
14.11.3 RECENT DEVELOPMENT 430
14.12 COUSIN SURGERY 431
14.12.1 COMPANY SNAPSHOT 431
14.12.2 PRODUCT PORTFOLIO 431
14.12.3 RECENT DEVELOPMENT 432
14.13 F. HOFFMANN-LA ROCHE LTD 433
14.13.1 COMPANY SNAPSHOT 433
14.13.2 REVENUE ANALYSIS 433
14.13.3 PRODUCT PORTFOLIO 434
14.13.4 RECENT DEVELOPMENT/NEWS 435
14.14 FITTERFLY HEALTHTECH PVT. LTD. 436
14.14.1 COMPANY SNAPSHOT 436
14.14.2 PRODUCT PORTFOLIO 436
14.14.3 RECENT DEVELOPMENT 437
14.15 MORPHIC MEDICAL, INC 438
14.15.1 COMPANY SNAPSHOT 438
14.15.2 PRODUCT PORTFOLIO 438
14.15.3 RECENT DEVELOPMENT 438
14.16 NOOM, INC. 439
14.16.1 COMPANY SNAPSHOT 439
14.16.2 PRODUCT PORTFOLIO 439
14.16.3 RECENT DEVELOPMENT 440
14.17 OMADA HEALTH INC 441
14.17.1 COMPANY SNAPSHOT 441
14.17.2 PRODUCT PORTFOLIO 441
14.17.3 RECENT DEVELOPMENT 441
14.18 RESHAPE LIFESCIENCES 442
14.18.1 COMPANY SNAPSHOT 442
14.18.2 REVENUE ANALYSIS 442
14.18.3 PRODUCT PORTFOLIO 443
1.1.7 RECENT DEVELOPMENT/NEWS 445
14.19 RAZIEL 448
14.19.1 COMPANY SNAPSHOT 448
14.19.2 PRODUCT PORTFOLIO 448
14.19.3 RECENT DEVELOPMENT 449
14.20 SPATZ FGIA INC. 450
14.20.1 COMPANY SNAPSHOT 450
14.20.2 PRODUCT PORTFOLIO 450
14.20.3 RECENT DEVELOPMENT 450
14.21 SANOFI 451
14.21.1 COMPANY SNAPSHOT 451
14.21.2 REVENUE ANALYSIS 451
14.21.3 PRODUCT PORTFOLIO 452
14.21.4 RECENT DEVELOPMENT 452
14.22 SANIONA 453
14.22.1 COMPANY SNAPSHOT 453
14.22.2 REVENUE ANALYSIS 453
14.22.3 PRODUCT PORTFOLIO 454
14.22.4 RECENT DEVELOPMENT 454
14.23 USGI MEDICAL 456
14.23.1 COMPANY SNAPSHOT 456
14.23.2 PRODUCT PORTFOLIO 456
14.23.3 RECENT DEVELOPMENT 456
14.24 VIVUS LLC. 457
14.24.1 COMPANY SNAPSHOT 457
14.24.2 PRODUCT PORTFOLIO 457
14.24.3 RECENT DEVELOPMENT/NEWS 458
14.25 VIKING THERAPEUTICS 460
14.25.1 COMPANY SNAPSHOTS 460
14.25.2 REVENUE ANALYSIS 460
14.25.3 PRODUCT PORTFOLIO 460
14.25.4 RECENT DEVELOPMENT 461
14.26 ZEALAND PHARMA 463
14.26.1 COMPANY SNAPSHOT 463
14.26.2 REVENUE ANALYSIS 463
14.26.3 PRODUCT PORTFOLIO 464
14.26.4 RECENT DEVELOPMENT/NEWS 465
15 QUESTIONNAIRE 466
16 RELATED REPORTS 469
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security